Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.
Blood Cancer J
; 4: e189, 2014 Mar 07.
Article
in En
| MEDLINE
| ID: mdl-24608733
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Blood Cancer J
Year:
2014
Document type:
Article
Affiliation country:
Suecia
Country of publication:
Estados Unidos